CellGenix, a global manufacturing leader of GMP-grade raw materials for cell therapy, gene therapy and tissue-engineered products, successfully completed the first phase of its headquarters’ expansion as more customers approach late-stage clinical development and commercialization.
In a first step, the company added additional space to its headquarters in Freiburg, Germany. Quality control, research and development laboratories as well as logistics and warehouse space have already been put into operation.
As the next step, a state-of-the-art, automated filling and freeze-drying line will be implemented in the existing GMP facility increasing finished product capacity for recombinant proteins by more than tenfold. This second phase of expansion is expected to be completed in the spring of 2019.
Positive clinical data, a supportive financing climate and clearer regulatory requirements have led to a strong growth in the cell and gene therapy space. This is predicted to persist. The building extension allows CellGenix to continue meeting the increasing demands for GMP-grade raw materials as more and more promising cell and gene therapies approach market authorization and commercialization.
Headquartered in Freiburg, Germany, CellGenix, a biopharmaceutical company, develops, manufactures, and markets cell and protein therapeutics for cancer and orthopedic patients. It offers ex vivo cell processing tools, such as GMP cytokines, research cytokines, serum-free media, cell culture bags, and closed kit systems.